286 related articles for article (PubMed ID: 22576341)
1. Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation.
Luedke E; Jaime-Ramirez AC; Bhave N; Carson WE
J Immunother; 2012 Jun; 35(5):367-73. PubMed ID: 22576341
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
3. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
4. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
Burtness B
Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
[TBL] [Abstract][Full Text] [Related]
6. The EGFR as a target for anticancer therapy--focus on cetuximab.
Baselga J
Eur J Cancer; 2001 Sep; 37 Suppl 4():S16-22. PubMed ID: 11597400
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab: from bench to bedside.
Vincenzi B; Zoccoli A; Pantano F; Venditti O; Galluzzo S
Curr Cancer Drug Targets; 2010 Feb; 10(1):80-95. PubMed ID: 20088790
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab: appraisal of a novel drug against colorectal cancer.
Hildebrandt B; le Coutre P; Nicolaou A; Köble K; Riess H; Dörken B
Recent Results Cancer Res; 2007; 176():135-43. PubMed ID: 17607921
[TBL] [Abstract][Full Text] [Related]
9. Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer.
López-Albaitero A; Ferris RL
Arch Otolaryngol Head Neck Surg; 2007 Dec; 133(12):1277-81. PubMed ID: 18086972
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
Ready N
Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
[TBL] [Abstract][Full Text] [Related]
11. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer.
Herbst RS; Kim ES; Harari PM
Expert Opin Biol Ther; 2001 Jul; 1(4):719-32. PubMed ID: 11727507
[TBL] [Abstract][Full Text] [Related]
12. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.
Martinelli E; De Palma R; Orditura M; De Vita F; Ciardiello F
Clin Exp Immunol; 2009 Oct; 158(1):1-9. PubMed ID: 19737224
[TBL] [Abstract][Full Text] [Related]
13. EGFR-targeting monoclonal antibodies in head and neck cancer.
Astsaturov I; Cohen RB; Harari PM
Curr Cancer Drug Targets; 2006 Dec; 6(8):691-710. PubMed ID: 17168674
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab.
Goldberg RM
Nat Rev Drug Discov; 2005 May; Suppl():S10-1. PubMed ID: 15962524
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor-targeted therapy for pancreatic cancer.
Xiong HQ; Abbruzzese JL
Semin Oncol; 2002 Oct; 29(5 Suppl 14):31-7. PubMed ID: 12422311
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor inhibition strategies in oncology.
Harari PM
Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
[TBL] [Abstract][Full Text] [Related]
17. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies.
Gialeli Ch; Kletsas D; Mavroudis D; Kalofonos HP; Tzanakakis GN; Karamanos NK
Curr Med Chem; 2009; 16(29):3797-804. PubMed ID: 19747140
[TBL] [Abstract][Full Text] [Related]
18. PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.
Nayak TK; Regino CA; Wong KJ; Milenic DE; Garmestani K; Baidoo KE; Szajek LP; Brechbiel MW
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1368-76. PubMed ID: 20155263
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.
Herbst RS; Langer CJ
Semin Oncol; 2002 Feb; 29(1 Suppl 4):27-36. PubMed ID: 11894011
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
